Novo Nordisk Foundation CEO surprised by mRNA Nobel Prize snub
The social significance of the mRNA-based Covid-19 vaccines is obvious, says Mads Krogsgaard Thomsen, who suggests that the technology may not have won because the committee did not manage to evaluate the vaccines in time.
by ulrich quistgaard, translated by catherine brett
The CEO of the Novo Nordisk Foundation, Mads Krogsgaard Thomsen, believes that David Julius and Ardem Patapoutian only won the Nobel Prize for medicine because the committee did not have time to properly evaluate the research behind the mRNA-based Covid-19 vaccines.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA approves Pfizer and Moderna Covid-19 booster shots
For subscribers
Novo Nordisk Foundation to boost pandemic prevention
For subscribers
